Peter Kießling

UCB Pharma (Germany) — Germany

Immunology and Microbiology · Life Sciences

19h-index2.4kcitations47works8.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunodeficiency and Autoimmune Disorders(12), Coagulation, Bradykinin, Polyphosphates, and Angioedema(12), Platelet Disorders and Treatments(11), Monoclonal and Polyclonal Antibodies Research(10), Hemophilia Treatment and Research(7)

Publications47 total

Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis
Journal of Comparative Effectiveness Research·2024· 6 citedOpen Access
Persistent headache in granulomatosis with polyangiitis
European Annals of Otorhinolaryngology Head and Neck Diseases·2024Open Access
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
Journal of Neurology Neurosurgery & Psychiatry·2024· 18 citedOpen Access
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis
Neurology Neuroimmunology & Neuroinflammation·2022· 23 citedOpen Access
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis
Neurology·2020· 136 citedOpen Access
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Blood Advances·2020· 107 citedOpen Access
Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations
Journal of Allergy and Clinical Immunology·2020· 112 citedOpen Access
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
Blood·2019· 5 citedOpen Access
S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY
HemaSphere·2019· 3 citedOpen Access
Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderate-to-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study (S43.001)
Neurology·2019· 16 cited
Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis
2017· 12 citedOpen Access
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Science Translational Medicine·2017· 195 cited
Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen.
Journal of Clinical Oncology·2012· 53 cited
Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.
Journal of Clinical Oncology·2011· 25 cited
Abstract 5506: Trabedersen (AP 12009) for the treatment of patients with advanced tumors: A phase I/II study
Cancer Research·2011· 1 cited
Author Response
Annals of Allergy Asthma & Immunology·2011
Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies
Clinical Immunology·2011· 108 cited
Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity
Allergy and Asthma Proceedings·2011· 11 cited
TIME TO RESPONSE OUTCOMES IN HEREDITARY ANGIOEDEMA Response
2011
Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks
Annals of Allergy Asthma & Immunology·2010· 16 cited
page 1 of 3Next →

Frequent Co-authors

Againdra K. Bewtra(13), Timothy Craig(12), Robyn J. Levy(12), Richard L. Wasserman(12), David Hurewitz(11), Jonathan A. Bernstein(9), Krystyna Obtułowicz(6), Avner Reshef(6), Stephen Jolles(6), Bruce Ritchie(5), Dumitru Moldovan(5), Todor Shirov(5), Vesna Grivcheva‐Panovska(5), Franz Woltering(5), Tadeusz Robak(5), Ute Massow(5), Ann Gardulf(4), Uwe Nicolay(4), O. Zenker(4), Isidro Jarque(4)